In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer

Heat-shock proteins as dendritic cell-targeting vaccines–getting warmer

Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium

Current status and future perspectives of dendritic cell-based cancer immunotherapy

Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer

Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome